Scott Skibo, MD currently serves as the Chief Medical Officer for Eon Health.  Prior to joining Eon Health in 2021, he has presented regularly at national scientific meetings focused on interventional pulmonology and lung cancer.  After finishing his pulmonary and critical care fellowship at Yale University in 2001, he gained over 20 years of experience in the thoracic oncology clinical space.  He co-developed the first system-wide incidental pulmonary nodule program in the United States in 2012.  He now leads the clinical team at Eon that oversees the quality and clinical outcomes for over 1000 US-based hospitals- helping to ensure the timely care for over 1 million patients per year.

Layah Liz Jacob is a PhD Scholar at CHRIST (Deemed to be University), Bengaluru, India under the guidance of Dr. Anuradha S. She holds an M.Sc in Clinical psychology from the same university and has been actively involved in the field of women and trauma for over 6 years. Alongside her supervisor, she was also a part of a collaborative research project with Miami university, focusing on enhancing life after cancer survivorship. Her doctoral research explores the interplay of existentialism, mortality awareness and spirituality in fostering post traumatic growth among cancer survivors, aiming to deepen understanding and support for their psychological recovery

Janusz Rak, MD, PhD is a Professor of Pediatrics and Jack Cole Chair in Pediatric Hematology/Oncology at McGill University, Investigator at the Research Institute of the McGill University Health Centre (RIMUHC), and Fellow of the Royal Society of Canada. His laboratory investigates how oncogenic events deregulate tumour microenvironment, orchestrate intercellular communication and trigger vascular alterations and systemic vascular paraneoplastic syndromes in cancer. The focal point of these studies are processes mediated by the exchange of extracellular vesicles (EVs), including exosomes, heterogeneous carriers of oncogenic, diagnostic and therapeutic cargo. This work is encapsulated in 220 research papers (45,000 citations).

Formerly Consultant Breast Surgeon at Imperial College Healthcare Trust ( at Charing Cross Hospital 2006 -2014 ) London SW6 .Previously Consultant Breast Surgeon  at Royal Marsden Hospital ,Fulham Road, London SW3.

Yu Aoki is a staff member in the Department of Medical Oncology at Tokyo Saiseikai Central Hospital and a visiting trainee in the Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Japan. She has 14 years of clinical experience as an oncologist and has authored several publications related to clinical research in gastrointestinal cancers. 

Xiao Meng, MD, Associate Professor, Associate Chief Physician, Master's Supervisor. She is engaged in research on lymphoma and the tumor immune microenvironment. She has presided over or participated in multiple provincial and municipal research projects, and her achievements have been selected for poster presentations at international conferences, with invitations for oral reports. She is a member of the Hematology Committee of Shandong Geriatric Medical Association, a member of the Hematology Committee of Shandong Association of Integrated Traditional Chinese and Western Medicine, and a member of the Hematology Branch of Jining Medical Association.

Shikha Bose is Professor of Pathology at Cedar~Sinai Medical Center and at the David Geffen School of Medicine, University of California, Los Angeles. She has authored more than 130 peer-reviewed scientific articles and has been an invited speaker at many national and international meetings. She has been involved in several NIH-sponsored studies. She is a member of the College of American Pathologists Breast Cancer Protocol Review Panel and the American Joint Committee on Cancer - Breast Cancer Staging System and helped formulate the recommendations for breast cancer staging and diagnosis. Dr. Bose was the Director of cytopathology for 22 years. 

Harald Stein is a former Director of the Institute of Pathology at the Free University of Berlin and Charité. He served as an editor of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues in 2001, 2008, and 2017. He is credited with the discovery of the molecules CD30 and Ki-67, as well as the characterization of anaplastic large cell lymphoma (ALCL). Over the course of his career, he has published more than 800 scientific articles on lymphomas.In 1989–1990, together with Professor Peter Isaacson (England), he co-founded the International Lymphoma Study Group (ILSG) to resolve longstanding differences in lymphoma classification between the United States and Europe. This effort culminated in 1994 with the development of a biologically sound and clinically relevant system known as the REAL (Revised European-American Lymphoma) classification, which successfully helped end the transatlantic classification dispute.

Dr Ali Abougazia is a Consultant Radiologist at University Hospitals of Derby and Burton NHS Foundation Trust, UK. He has over 14 years of experience in clinical radiology, with Special interest in breast cancer imaging. He is a Fellow of the Royal College of Radiologists (FRCR) and holds a Master’s degree in clinical Radiology. Dr. Abougazia is research active, and presents his work at local, national and international scientific meetings. His research focuses on advancing the diagnosis of breast cancer using traditional and innovative imaging techniques

Irma Shamatava earned her Ph.D. in Electrical and Electronics Engineering from Tbilisi State University (TSU) in 2015. Her research interests include magnetic nanoparticle hyperthermia for deep tissue cancer treatment. She is a member of both the Dartmouth Electromagnetic Sensing Group and the TSU team, where she contributes to experiment design, modeling, and optimization of magnetic nanoparticle hyperthermia treatment methodologies for clinical applications. She has presented her work at the Society of Thermal Medicine Conference annual meetings.

Prof.Iris Manor-Binyamini is an Associate Professor in the Department of Social Work at Tel-Hai University, Israel. One of her research areas focuses on psycho-oncology, cancer survivorship, and the psychosocial experiences of culturally diverse and underserved populations. Drawing on qualitative and mixed-methods approaches, she examines how cultural, familial, and social contexts shape coping, well-being, and healthcare experiences among individuals facing serious illness and disabilities. Her recent work has focused on breast cancer survivorship among Bedouin women, highlighting the role of family support, body image, and culturally responsive psychosocial care in promoting well-being within minority communities.

Minmin Hou is a Professor of Gynecologic Oncology at West China Second University Hospital, Sichuan University, with 20 years of clinical experience. She has long been engaged in frontline clinical work and specializes in surgical treatment for various gynecologic malignancies. In addition, she has presided over multiple research projects and published numerous papers in relevant domestic and international journals.

Dr. Luis I. Terrazas is a full professor at Facultad de Estudios Superiores Iztacala, UNAM, México.  Has 25 years’ experience as an Immunologist, with more than 130 publications in the field of immunoregulation of inflammatory diseases and immunoparasitology. His group has developed several preclinical models to study colorectal cancer and recently started to analyze the development of this cancer in Mexican patients. 

Jekaterina Erenpreisa graduated in general medicine, defended two doctoral theses (PhD 1971 and Dr.hab. med. 1991) in normal and cancer cell nucleus organisation, to whom devoted 20 years of the first part of the scientific career. Further 30 years are devoted to the fundamental, systems-level features of cancer cells: polyploidy, embryonality, and resistance to treatments. Until June 2026 - Leading researcher of the Latvian Biomedical Research &Study Centre (oncology). A Full Member of the Latvian Academy of Sciences (2003), State Emeritus scientist (2014). H-index 42.

Dr. Rabia Zulfiqar is a Research Scientist, Medical Entrepreneur, and Executive Director at Dinkum Publishers, United Kingdom. She has extensive experience in medical research, academic publishing, and scientific communication. She has authored more than 125 peer-reviewed publications and has contributed to research across public health, clinical medicine, oncology, and epidemiology. 13 years’ experience as a Cancer Epidemiologist/Research Scientist at Dinkum Publishers, United Kingdom. She regularly publishes in the public health & epidemiology literature, and regularly presents data at national and international scientific meetings. His professional interests include evidence-based medicine, academic leadership, research capacity building, and advancing global scientific collaboration.

Prof. Dr. Saima Bukhari is Professor of Pharmacology at Ayub Medical College, Abbottabad, Pakistan. An accomplished pharmacologist, medical educator, and clinical researcher, she holds an MBBS and an M.Phil. in Pharmacology. Her research interests include clinical pharmacology, rational therapeutics, antimicrobial resistance, infectious diseases, pharmacovigilance, drug safety, artificial intelligence in healthcare, women's health, and public health. Prof. Dr. Bukhari has authored numerous peer-reviewed publications in national and international journals and actively contributes to undergraduate and postgraduate medical education. She also serves as a reviewer for international scientific journals and is committed to advancing evidence-based medicine, research collaboration, and healthcare innovation through education and scientific research.

Dr. Caiyue Li is an Associate Professor at The Eighth Affiliated Hospital of Southern Medical University, China. She received her Ph.D. from the Guangzhou Institutes of Biomedicine and Health, University of Chinese Academy of Sciences (China) in 2016. From 2016 to 2025, she conducted postdoctoral research and served as a Senior Scientist at leading U.S. institutions, including The University of Texas MD Anderson Cancer Center, Tulane University School of Medicine, and Louisiana State University Health Sciences Center. Her research focuses on the molecular mechanisms of cancer and precision targeted therapy, particularly p53 signaling, cancer biomarkers, and therapeutic resistance. She has published 14 SCI papers, holds six Chinese patents, serves as a reviewer for 19 SCI journals, including Cancer Research and Cell Death & Differentiation, and is an Associate Editor of Frontiers in Oncology.

Scott Skibo, MD currently serves as the Chief Medical Officer for Eon Health.  Prior to joining Eon Health in 2021, he has presented regularly at national scientific meetings focused on interventional pulmonology and lung cancer.  After finishing his pulmonary and critical care fellowship at Yale University in 2001, he gained over 20 years of experience in the thoracic oncology clinical space.  He co-developed the first system-wide incidental pulmonary nodule program in the United States in 2012.  He now leads the clinical team at Eon that oversees the quality and clinical outcomes for over 1000 US-based hospitals- helping to ensure the timely care for over 1 million patients per year.

Janusz Rak, MD, PhD is a Professor of Pediatrics and Jack Cole Chair in Pediatric Hematology/Oncology at McGill University, Investigator at the Research Institute of the McGill University Health Centre (RIMUHC), and Fellow of the Royal Society of Canada. His laboratory investigates how oncogenic events deregulate tumour microenvironment, orchestrate intercellular communication and trigger vascular alterations and systemic vascular paraneoplastic syndromes in cancer. The focal point of these studies are processes mediated by the exchange of extracellular vesicles (EVs), including exosomes, heterogeneous carriers of oncogenic, diagnostic and therapeutic cargo. This work is encapsulated in 220 research papers (45,000 citations).

Harald Stein is a former Director of the Institute of Pathology at the Free University of Berlin and Charité. He served as an editor of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues in 2001, 2008, and 2017. He is credited with the discovery of the molecules CD30 and Ki-67, as well as the characterization of anaplastic large cell lymphoma (ALCL). Over the course of his career, he has published more than 800 scientific articles on lymphomas.In 1989–1990, together with Professor Peter Isaacson (England), he co-founded the International Lymphoma Study Group (ILSG) to resolve longstanding differences in lymphoma classification between the United States and Europe. This effort culminated in 1994 with the development of a biologically sound and clinically relevant system known as the REAL (Revised European-American Lymphoma) classification, which successfully helped end the transatlantic classification dispute.